Ash 2021 preview – small increases and big falls

Last week's release of this year’s crop of Ash abstracts seems to have prompted more fallers than risers in terms of share price activity. Sanofi’s fitusiran, one of the projects that the French group admitted last week would be set back 18 months or so, should draw attention with data from one of its suite of phase 3 haemophilia studies.

More dramatic moves – and not in the right direction – occurred for ALX Oncology and Syndax Pharmaceuticals. Perhaps the situation for these groups will improve with the actual presentations, which will be given in just over a month’s time.